Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 25

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 25
---
 The Nasdaq Stock Market and is currently available at ir.supernus.com/corporate-governance. The Governance and Nominating Committee’s responsibilities include: • making recommendations to our Board of Directors regarding candidates for directorships and assisting the Board of Directors in identifying and recruiting such individuals; • reviewing and making recommendations to our Board of Directors regarding qualified individuals to serve as committee members on the various Board committees; • reviewing the performance, operations and composition of the Board of Directors; • evaluating the need for continuing education of directors as specifically related to service on the Board of Directors and board committees; • assessing and reviewing our corporate governance guidelines and recommending any changes to the Board of Directors; • monitoring and safeguarding the independence of the Board of Directors and reviewing potential conflicts of interest between a director and the Company or a member of senior management; • reporting and making recommendations to our Board concerning governance matters; • annually reviewing the Governance and Nominating Committee’s performance; and • periodically reviewing the Governance and Nominating Committee charter. Science Committee On February 23, 2023, the Board formalized the existing practice of certain board members and members of management meeting for focused discussions on the Company’s research and development programs by forming a Board science committee (the “Science Committee”). The members of the Science Committee are:Dr. Barlow, who is the chair of the committee, and Dr. Gemayel. The Science Committee is responsible for engaging in discussions with management on the Company’s research and development programs and reporting on those discussions to the Board. The Science Committee held four (4) meetings during the last fiscal year. Other Committees Our Board of Directors may establish other committees as it deems necessary or appropriate from time to time. 15 Transactions with Related Persons Procedures for Related Person Transactions Our Audit Committee is responsible for reviewing and approving all material transactions with any related person on a continuing basis. Related persons can include any of our directors or officers, holders of 5% or more of our voting securities and their immediate family members. This obligation is set forth in writing in our Audit Committee charter. We may not enter into a related person transaction unless our Audit Committee has reviewed and approved such transaction. Transactions with Related Persons and Certain Control Persons Other than the transactions set forth below, since January 1, 2024, there has not been any transaction or series of transactions to which we were or are a party in which the amount involved exceeded or exceeds $120,000 and in which any director, executive officer, holder of more than